Drug intelligence / Profile preview

KAN-ONCO-03

Development stage: Preclinical
Lead developer: Kantify
Modality: Small Molecules

Overview

KAN-ONCO-03 is a first-in-class small molecule designed to modulate the ubiquitination pathway for the treatment of various cancers (pan-cancer). Discovered using Kantify's Sapian™ AI platform, the drug is being developed in collaboration with the Leiden University Medical Center (LUMC). As a modulator of the protein degradation machinery, KAN-ONCO-03 represents a novel approach to oncology by targeting the ubiquitination process, which is often dysregulated in malignant cells. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on KAN-ONCO-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAN-ONCO-03.

Explore the full profile